<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01398423</url>
  </required_header>
  <id_info>
    <org_study_id>INV144-201</org_study_id>
    <nct_id>NCT01398423</nct_id>
  </id_info>
  <brief_title>INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria</brief_title>
  <official_title>A 12 Week, Phase II Trial of the Safety, Pharmacokinetics, and Efficacy of INV-144 Compared With Losartan Potassium in Patients With Hypertension and Type 2 Diabetes Mellitus With Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InVasc Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InVasc Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, active control trial to determine the safety, efficacy and&#xD;
      pharmacokinetics of INV-144 versus losartan potassium plus placebo in subjects with&#xD;
      hypertension and Type 2 diabetes mellitus with nephropathy as evidenced by albuminuria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, randomized, double-blind, parallel-group, active-control trial is designed to&#xD;
      evaluate the safety and efficacy of INV-144 versus losartan plus placebo co-administered once&#xD;
      daily for 12 weeks in subjects who have type 2 diabetes and hypertension with nephropathy as&#xD;
      evidenced by albuminuria.&#xD;
&#xD;
      Approximately 92 adult subjects will be enrolled and randomized in a 1:1 ratio to receive&#xD;
      either INV-144 or losartan plus placebo once daily for 12 weeks. The goal is to have&#xD;
      approximately 80 subjects complete the entire study.&#xD;
&#xD;
      The trial will consist of a 4-week open-label losartan run-in period, a 12-week double-blind&#xD;
      active treatment period, and a 4-week safety follow-up period. Efficacy will be evaluated by&#xD;
      measurement of UACR, systolic and diastolic blood pressure, and the HOMA-IR ratio. Safety&#xD;
      will be monitored throughout the study by evaluation of adverse events (AEs), physical&#xD;
      examinations (PEs), clinical laboratory results, vital signs, and electrocardiograms (ECGs).&#xD;
&#xD;
      Blood samples for PK analysis will be obtained in a subset of approximately 22 subjects, at 2&#xD;
      to 4 sites, to ensure that PK data are obtained from a minimum of 9 subjects in each&#xD;
      treatment arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety will be monitored throughout the study by evaluation of adverse events (AEs), physical examinations (PEs), clinical laboratory results, vital signs, and electrocardiograms (ECGs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy will be evaluated by measurement of UACR, systolic and diastolic blood pressure, and the HOMA-IR ratio.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Active control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INV-144</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Control</intervention_name>
    <description>Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)</description>
    <arm_group_label>Active control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INV-144</intervention_name>
    <description>INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)</description>
    <arm_group_label>INV-144</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women, 18 to 85 years of age, inclusive.&#xD;
&#xD;
          2. Able and willing to understand and provide written informed consent.&#xD;
&#xD;
          3. Documented hypertension defined by 1 of the following:&#xD;
&#xD;
             Currently treated with antihypertensive medications, or Untreated with a seated&#xD;
             systolic blood pressure (mean of 3 readings) between 126 and 180 millimeters of&#xD;
             mercury (mm Hg).&#xD;
&#xD;
          4. Documented type 2 diabetes mellitus defined by 1 of the following:&#xD;
&#xD;
             Currently treated with anti-diabetic medication (oral and/or insulin), or Fasting&#xD;
             serum glucose level ≥126 mg/dL.&#xD;
&#xD;
          5. Documented nephropathy evidenced by a UACR of 300 to 3000 mg/g.&#xD;
&#xD;
          6. Both men and women of child bearing potential (i.e., not surgically sterile or&#xD;
             post-menopausal defined as age &gt;40 years without menses for ≥2 years) must agree to&#xD;
             use 1 of the following forms of reliable contraception:&#xD;
&#xD;
        Abstinence, meaning a total lack of sexual activity, Oral contraceptives (&quot;the pill&quot;) or&#xD;
        other hormonal contraceptive methods, Intrauterine device, Double-barrier method (diaphragm&#xD;
        or condom plus spermicidal cream), or If female, male partner sterilization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Required use of an ACE inhibitor, ARB, direct renin inhibitor, or aldosterone&#xD;
             antagonist other than study drug, while on the study.&#xD;
&#xD;
          2. Systolic blood pressure &gt;180 mm Hg (mean of 3 seated readings, 5 minutes apart, using&#xD;
             the subject's dominant arm).&#xD;
&#xD;
          3. Chronic kidney disease stage 4 or higher defined as an estimated glomerular filtration&#xD;
             rate &lt;30 mL/min per 1.73 m2 (abbreviated MDRD equation).&#xD;
&#xD;
          4. Hepatic impairment defined by serum alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST)&gt;2 x the upper limit of normal.&#xD;
&#xD;
          5. Diagnosis of type 1 diabetes or non-diabetic renal disease, including but not limited&#xD;
             to renal-artery stenosis, primary glomerular disease, autoimmune renal diseases, etc.&#xD;
&#xD;
          6. Severe anemia defined as hemoglobin &lt; 8 g/dL.&#xD;
&#xD;
          7. Congestive heart failure with New York Heart Association Class II, III, or IV&#xD;
             symptoms.&#xD;
&#xD;
          8. Thiamine (Vitamin B1) deficiency or known alcohol abuse within the past year. If&#xD;
             alcohol abuse is suspected, subject must have a normal thiamine blood level documented&#xD;
             prior to study entry.&#xD;
&#xD;
          9. Any radiocontrast-facilitated study within 30 days prior to Study Day 1.&#xD;
&#xD;
         10. Cerebrovascular accident within the previous 6 months, or have had a transient&#xD;
             ischemic attack within the previous year.&#xD;
&#xD;
         11. Pregnant or nursing women; women of childbearing potential must have a negative serum&#xD;
             pregnancy test at Screen.&#xD;
&#xD;
         12. Known adverse reaction to losartan and/or ALA.&#xD;
&#xD;
         13. Participation in another clinical trial or have received an investigational agent for&#xD;
             any reason within 30 days of Study Day 1.&#xD;
&#xD;
         14. Any other condition that in the opinion of the Investigator, may adversely affect the&#xD;
             safety of the subject, the subject's ability to complete the study, or the outcome of&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Schaeffer</last_name>
    <role>Study Director</role>
    <affiliation>InVasc Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reisterstown</city>
        <state>Maryland</state>
        <zip>21136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aiken</city>
        <state>South Carolina</state>
        <zip>29801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>August 5, 2012</last_update_submitted>
  <last_update_submitted_qc>August 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes mellitis</keyword>
  <keyword>Nephropathy</keyword>
  <keyword>Albuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

